

2 March 2026

[submitted electronically via: [HouseHealthandHumanServices@rilegislature.gov](mailto:HouseHealthandHumanServices@rilegislature.gov)]

The Honorable Susan Donovan  
Chair, House Committee on Health & Human Services  
State House  
82 Smith Street  
Providence, RI 02903

**RE: SUPPORT – H7424 – AN ACT RELATING TO BUSINESSES AND PROFESSIONS – COLLABORATIVE PHARMACY PRACTICE**

Dear Chair Donovan and Members of the Committee:

My name is Todd Brothers, PharmD, BCCCP, BCPS. I am a Clinical Associate Professor at the University of Rhode Island College of Pharmacy and a practicing critical care pharmacist in Rhode Island. I am writing in strong support of **House Bill 7424**, along with its companion bill introduced in the Senate. This legislation modernizes Rhode Island's collaborative pharmacy practice statute by allowing pharmacists to enter into collaborative practice agreements directly with licensed providers and by eliminating the unnecessary board approval process prior to implementation.

Collaborative pharmacy practice agreements are structured, written agreements that allow pharmacists with advanced training to initiate, adjust, monitor, or discontinue drug therapy pursuant to an agreed-upon protocol. These models are evidence-based and widely utilized across the country to improve chronic disease management, medication safety, and healthcare access. In real-world practice, administrative delays in approving agreements can slow patient access to care without adding meaningful patient safety protections. H7424 maintains accountability by requiring written agreements, annual review, adherence to clinical guidelines, and board oversight authority if concerns arise. What it removes is duplicative pre-approval bureaucracy that impedes timely team-based care.

From a clinical standpoint, pharmacists are doctoral-trained medication experts. Collaborative practice allows healthcare teams to respond efficiently to conditions such as diabetes, hypertension, anticoagulation management, heart failure, and infectious diseases, where timely medication adjustment directly impacts hospitalization and long-term outcomes.

Importantly, this bill passed the House in 2025, reflecting prior recognition of its value. H7424 strengthens interdisciplinary care, improves patient access, and aligns Rhode Island with national standards for team-based healthcare delivery.

For these reasons, I respectfully urge the Committee to support House Bill 7424 and its Senate companion bill.

Thank you for your consideration and your continued commitment to improving healthcare in Rhode Island.

Respectfully submitted,



Todd Brothers, PharmD, BCCCP, BCPS.  
Clinical Associate Professor College of Pharmacy  
Department of Pharmacy Practice and Clinical Research  
University of Rhode Island